These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 4120302)

  • 1. Loss of isoantigens A, B and H in prostate.
    Gupta RK; Schuster R; Christian WD
    Am J Pathol; 1973 Mar; 70(3):439-47. PubMed ID: 4120302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoantigens A, B and H in benign and malignant lesions of breast.
    Gupta RK; Schuster R
    Am J Pathol; 1973 Aug; 72(2):253-7. PubMed ID: 4807589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are blood group isoantigens lost from malignant prostatic epithelium? Immunohistochemical support for the preservation of the H isoantigen.
    Vowden P; Lowe AD; Lennox ES; Bleehen NM
    Br J Cancer; 1986 Mar; 53(3):307-12. PubMed ID: 2421753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma.
    Wernert N; Seitz G; Achtstätter T
    Pathol Res Pract; 1987 Oct; 182(5):617-26. PubMed ID: 2446293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human prostate tissue antigens defined by murine monoclonal antibodies.
    Starling JJ; Sieg SM; Beckett ML; Wirth PR; Wahab Z; Schellhammer PF; Ladaga LE; Poleskic S; Wright GL
    Cancer Res; 1986 Jan; 46(1):367-74. PubMed ID: 2415250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia.
    Brannen GE; Coffey DS
    Cancer Treat Rep; 1977; 61(2):211-6. PubMed ID: 68825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ABH isoantigens and the normal and tumorous urogenital tissues (author's transl)].
    Kaneta T
    Nihon Hinyokika Gakkai Zasshi; 1979 Dec; 70(12):1401-13. PubMed ID: 94371
    [No Abstract]   [Full Text] [Related]  

  • 11. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
    Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
    Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
    Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
    Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
    Horoszewicz JS; Kawinski E; Murphy GP
    Anticancer Res; 1987; 7(5B):927-35. PubMed ID: 2449118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T; Garg S
    Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical localization of prostate carcinoma-associated antigens.
    Wright GL; Beckett ML; Starling JJ; Schellhammer PF; Sieg SM; Ladaga LE; Poleskic S
    Cancer Res; 1983 Nov; 43(11):5509-16. PubMed ID: 6193873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
    Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
    Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological tissue markers in benign and malignant disease of the human prostate.
    Chastonay P; Hurlimann J; Gardiol D
    Virchows Arch A Pathol Anat Histopathol; 1986; 410(3):221-9. PubMed ID: 2432724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytologic losses of isoantigens A, B, and H (O) in the endometrium and brain.
    Gupta RK
    Am J Clin Pathol; 1976 Aug; 66(2):390-4. PubMed ID: 986115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Histochemical study of ABH antigens in the prostate].
    Niimura T
    Nihon Hinyokika Gakkai Zasshi; 1985 Jun; 76(6):806-13. PubMed ID: 4068422
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
    De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
    Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.